VERO Biotech
  • Our Story
    • Overview
    • Leadership Team
    • Board of Directors
  • Solutions
    • Overview
    • Publications
  • Updates
    • Overview
    • In the News
  • Opportunities
  • Engagement
  • MEMBER LOGIN
  • Menu Menu
  • MEMBER LOGIN

In the News

You are here: Home1 / Updates2 / In the News
  • https://gabio.org

    VERO Biotech Awarded ‘Deal of the Year’ by Georgia Biotech

    March 4, 2021

  • https://pulmonaryhypertensionnews.com

    VERO Biotech Named Top Two Stories of 2020 by Pulmonary Hypertension News

    January 5, 2021

  • www.rtmagazine.com

    Inhaled Nitric Oxide: Past, Present, and Future

    June 25, 2020

  • www.respiratorytherapy.ca

    Respiratory Therapy Newsletter June

    June 2, 2020

  • https://www.medscape.com

    Inhaled Nitric Oxide Explored for COVID-19 Oxygenation

    May 14, 2020

  • https://www.webmd.com

    Inhaled Nitric Oxide Explored for COVID-19 Oxygenation

    May 14, 2020

  • https://www.respiratorytherapy.ca

    Case Report Details Success of Tankless Delivery System

    May 13, 2020

  • www.pulmonaryhypertensionnews.com

    At-home System of Inhaled Nitric Oxide Treats PAH Patient Infected With COVID-19

    May 11, 2020

  • www.ptcommunity.com

    Home Use of GENOSYL® Delivery System (DS) to Administer GENOSYL® (nitric oxide) gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine

    May 6, 2020

  • www.galusaustralis.com

    Global Inhaled Nitric Oxide (NO) Delivery Systems Market Research Report 2020 by COVID-19 Pandemic Economic Emergency Analysis, Industry Size, Future Growth Analysis by 2027

    May 01, 2020

  • www.empr.com

    Pipeline: Immunotherapies and Other Investigational Therapies for COVID-19

    April 30, 2020

  • www.ajc.com

    Georgia manufacturing shaken by virus, but some ramp up

    April 20, 2020

  • www.itresearchbrief.com

    Trends of Inhaled Nitric Oxide (NO) Delivery Systems Market Reviewed for 2020 with Industry Outlook to 2025

    April 20, 2020

  • www.medicaldevice-network.com

    VERO Biotech uses expanded access emergency for iNO delivery system

    March 27, 2020

  • www.biocentury.com

    COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

    March 27, 2020

  • www.finance.yahoo.com

    FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

    March 26, 2020

  • www.reuters.com

    BRIEF-FDA Grants Vero Biotech Expanded Access Emergency Use For Treatment Of Patients With COVID-19, With Genosyl Ds

    March 26, 2020

  • www.pulmonaryhypertensionnews.com

    COVID-19 Patient with PH Treated with iNO Via Genosyl, VERO Biotech Announces

    March 25, 2020

  • www.biocentury.com

    Regulatory roundup: BioMarin poised to have first U.S., EU hemophilia gene therapy; plus Allergan, Eisai, FibroGen, ViiV and Vero

    December 24, 2019

Contact Info

  • 387 Technology Circle NW
    Suite 125
    Atlanta, Georgia 30313

  • contactus@vero-biotech.com

  • 877-337-4118 (Product Inquiries)

Quick Links

  • Our Story
  • Solutions
  • Publications
  • Opportunities
  • Prescribing Information
  • Engagement
  • Employees

Medical Inquiries

For medical inquiries, to report an adverse event, other safety-related information, or product complaints for a company product.

REQUEST FORM

  • Check our Privacy Policy
  • Facebook
  • LinkedIn
  • Instagram
© Copyright - VERO Biotech. All rights reserved. VERO Biotech and GENOSYL are registered trademarks of VERO Biotech, LLC.
Indication & safety information Indication & safety info
EXPAND
Indication & Safety Information

GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

  • GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
  • Methemoglobin, NO2 and PaO2 should be monitored during nitric oxide administration.
  • In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema. The most common adverse reaction is hypotension.
  • Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
  • Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
  • See package insert for additional Important Safety Information.